Spotlight on Rheumatology

Credits: 1.00 CME / CNE
Clinical Reflections®: Achieving Success in RA Assessment and Management: A Learner Pathway to Improve Patient Outcomes
Jeffrey Curtis, MD, MS, MPH
Postgraduate Institute for Medicine

Clinical Reflections®: Achieving Success in RA Assessment and Management: A Learner Pathway to Improve Patient Outcomes

Start

Jointly Provided By

Activity Details

Free CME/CNE
1 AMA PRA Category 1 Credit
1 ANCC contact hour
0.5 APRN contact hour
Released: October 12, 2017
Expires: October 12, 2018
1 hour to complete
No registration required

Media

Internet

Target Audience

This activity has been designed to meet the educational needs of clinicians and registered nurses who manage patients with rheumatoid arthritis (RA).

Learning Objectives

After completing this activity, the participant will demonstrate the ability to:

  1. Discriminate between the effects of the tumor necrosis factor alpha (TNFα) and interleukin 6 (IL-6) signaling pathways in the pathophysiology of rheumatoid arthritis (RA) and provide a rationale for anti-cytokine therapy as a treatment approach
  2. Incorporate validated and guideline-recommended disease activity monitoring to guide appropriate management for patients with rheumatoid arthritis
  3. Develop individualized treatment plans for patients with rheumatoid arthritis that integrate new and emerging targeted and non-TNF disease modifying antirheumatic drugs (bMARDs) based on safety and efficacy data
  4. Distinguish between TNF cycling and switching and prepare treatment plans that improve patient outcomes based on an understanding of the differences between the 2 options
  5. Integrate shared decision making and other patient education strategies for patients with rheumatoid arthritis

Activity Description

Rheumatoid arthritis (RA) is a chronic disease with devastating consequences if not optimally managed early in the disease process. To effectively treat RA, appropriate treatments need to be selected, disease and treatment outcomes must be measured regularly, and patients need to be engaged in their own care. These concepts underpin the treat-to-target (T2T) approach endorsed by the European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR). The availability of several new treatments beyond conventional disease modifying antirheumatic drugs (DMARDs) and anti-tumor necrosis factor (anti-TNF) inhibitors also increases the complexity of effective disease management.

This unique educational initiative harnesses the power of reflection and recognition of suboptimal approaches to patient management to allow you to rethink clinical decisions based on the scenarios presented and to modify management plans accordingly. You can compare your responses to interactive questions with those of your peers and learn from our expert faculty.

Faculty

Jeffrey R. Curtis, MD, MS, MPH (Chair)
William J. Koopman Endowed Professor in Rheumatology and Immunology
Professor of Medicine, Division of Clinical Immunology and Rheumatology
Director, University of Alabama at Birmingham (UAB) Arthritis Clinical Intervention     Program
Co-Director, UAB Center for Education and Research on Therapeutics (CERTS) of Musculoskeletal Disorders
Co-Director, UAB Pharmacoepidemiology and Pharmacoeconomics (PEER) Unit
University of Alabama at Birmingham
Birmingham, AL


Martin Jan Bergman, MD, FACR, FACP, FCPP
Clinical Associate Professor of Medicine
Drexel University School of Medicine
Philadelphia, PA
Chief, Division of Rheumatology
Taylor Hospital
Ridley Park, PA


Peter C. Taylor, MA, BM, BCh, PhD, FRCP, FRCPE
Norman Collison Professor of Musculoskeletal Sciences
Fellow, St. Peter’s College
Head of Clinical Sciences, Biomedical Research Unit Inflammation Theme
Botnar Research Centre
University of Oxford
Oxford, England (UK)


Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

  • Jeffrey R. Curtis, MD, MS, MPH, has affiliations with AbbVie, Amgen, Bristol-Myers Squibb, Corrona, Genentech, Janssen, Lilly, Myriad, and Pfizer (Consulting Fees); and AbbVie, Amgen, Bristol-Myers Squibb, Corrona, Genentech, Janssen, Lilly, Myriad, and Pfizer (Contracted Research).
  • Martin Jan Bergman, MD, FACR, FACP, FCPP, has affiliations with AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Genentech, GlaxoSmithKline, Janssen, Novartis, Pfizer, and Sanofi (Consulting Fees); AbbVie, Celgene, Novartis, and Sanofi (Fees for Non-CME/CE Services Received Directly from a Commercial Interest or Their Agents); Johnson & Johnson, Merck, and Pfizer (Ownership Interest).
  • Peter C. Taylor, MA, BM, BCh, PhD, FRCP, FRCPE, has affiliations with AbbVie, Biogen, Galapagos, GlaxoSmithKline, Janssen, Lilly, Pfizer, Sanofi, and UCB (Consulting Fees); and Abide Therapeutics, Celgene, Lilly, and UCB (Contracted Research).

RMEI Medical Education, LLC

  • Jacqui Brooks, MBBCh, MRCPsych, has no affiliations with commercial interests relative to the content to disclose.
  • Tania Dickson, PhD, has no affiliations with commercial interests relative to the content to disclose.
  • Jessica Hatch has no affiliations with commercial interests to disclose.

Postgraduate Institute for Medicine
The following PIM planners and managers, Judi Smelker-Mitchek, RN, BSN, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, and Jan Schultz, MSN, RN, CHCP, have nothing to disclose.

Physician Continuing Medical Education

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and RMEI Medical Education, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Postgraduate Institute for Medicine is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.  This educational activity for 1 contact hour is provided by the Postgraduate Institute for Medicine. Designated for 0.5 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.

How to Receive Credit

By reviewing the course content and successfully completing the post test and evaluation, physicians, nurse practitioners, and PAs are entitled to receive up to 1 AMA PRA Category 1 Credit(s)™, 1 ANCC contact hour, and 0.5 APRN contact hours. A statement of credit will be available to print from your user history page. Users must:

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the activity evaluation.

Physicians, nurse practitioners, and PAs who successfully complete the post test and evaluation will receive CME credit. You must score 75% or higher on the post test to receive credit for this activity. All other participants who successfully complete the post test and evaluation will receive a certificate of participation.

Statement of Commercial Support

This activity is supported by an independent educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 9.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Rheumatology Presentations

0.75 CME
Postgraduate Institute for Medicine
Global Perspectives in RA: The Role of New Biologics for Optimal Management

Global Perspectives in RA: The Role of New Biologics for Optimal Management

Start

Activity Details

Free CME
0.75 AMA PRA Category 1 Credits
Released: August 30, 2018
Expires: August 29, 2019
45 minutes to complete

Jointly Provided By

This activity is jointly provided by Postgraduate Institute for Medicine and RMEI Medical Education, LLC.

Media

Internet

Target Audience

Clinicians involved in the care of patients with rheumatoid arthritis (RA).

Learning Objectives

  • Describe involvement of the IL-6 signaling pathway in the pathophysiology, extra-articular symptomology, and associated comorbidities of rheumatoid arthritis (RA), and the role of cytokine-targeted therapy in the treatment of RA
  • Incorporate validated and guideline-recommended RA disease activity monitoring to guide appropriate management of patients
  • Use a treat-to-target approach for managing RA that personalizes therapy by cycling or switching treatment options in nonresponsive patients, and takes into account data for new and emerging biologic and targeted synthetic DMARDs
  • Develop individualized RA treatment strategies that incorporate patient preferences, shared decision making, and patient education

 

Faculty

Paul Emery, MA, MD, FRCP, FMedSci (Chair)
Arthritis Research UK Professor of Rheumatology
Leeds Institute of Rheumatic & Musculoskeletal Medicine, University of Leeds
Director, Leeds Biomedical Research Centre
Leeds Teaching Hospitals NHS Trust
Leeds, England (UK)


Jonathan Kay, MD
Professor of Medicine
Timothy S. and Elaine L. Peterson Chair in Rheumatology
Director of Clinical Research, Division of Rheumatology
University of Massachusetts Medical School
Worcester, Massachusetts (USA)


Josef S. Smolen, MD
Professor of Medicine
Chairman, Division of Medicine and Department of Medicine 3
Medical University of Vienna
Vienna, Austria (Europe)


Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

  • Paul Emery, MA, MD, FRCP, FMedSci, has affiliations with AbbVie, BMS, MSD, Pfizer, and Roche (Contracted Research/Grants); AbbVie, BMS, MSD, Novartis, Pfizer, Roche, and UCB (Consulting Fees); and AbbVie, BMS, MSD, Novartis, Roche, and UCB (Speakers' Bureau).
  • Jonathan Kay, MD, has affiliations with Eli Lilly and Company, Gilead, Pfizer, and UCB (Contracted Research/Grants); and Amgen, Boehringer Ingelhelm GmbH, Celgene, Celltrion Healthcare, Janssen, Merck Sharpe & Dohme, Myriad Genetics, Pfizer, Roche, Samsung Bioepis, and Sandoz (Consulting Fees). 
  • Josef S. Smolen, MD, has affiliations with AbbVie, Astra-Zeneca, Eli Lilly and Company, Janssen, MSD, Pfizer, and Roche (Contracted Research/Grants); and AbbVie, Amgen, Astra-Zeneca, Astro, BMS, Celgene, Celltrion, Chugai, Gilead, Glaxo, Eli Lilly and Company, ILTOO, Janssen, Medimmune, MSD, Novartis-Sandoz, Pfizer, Roche, Samsung, Sanofi, and UCB (Consulting Fees).

Planners and Managers
The PIM planners and managers have nothing to disclose. RMEI Medical Education, LLC planners and managers have nothing to disclose.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and RMEI Medical Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.


PHYSICIAN CONTINUING MEDICAL EDUCATION
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

How to Receive Credit

By reviewing the course content and successfully completing the post-test and evaluation, physicians, nurse practitioners, and PAs are entitled to receive up to 0.75 AMA PRA Category 1 Credit(s)™. A statement of credit will be available to print from your user history page. Users must:

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the activity evaluation.

Physicians, nurse practitioners, and PAs who successfully complete the post-test and evaluation will receive CME credit. You must score 75% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation. If you would like to contact Postgraduate Institute for Medicine, please email information@pimed.com.

YOUR FEEDBACK IS IMPORTANT!

Complete the Evaluation form for this activity and be entered into a drawing for a $100* Amazon Gift card.
*The expense for this gift card is solely funded by RMEI Medical Education, LLC. No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a monthly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your email address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

The activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

1.50 CME
Postgraduate Institute for Medicine
Early and Aggressive Approaches to RA Management to Minimize Disease Progression and Improve Quality of Life

Early and Aggressive Approaches to RA Management to Minimize Disease Progression and Improve Quality of Life

Start

Activity Details

Free CME
1.5 AMA PRA Category 1 Credits
Released: May 1, 2018
Expires: June 17, 2019
1.5 hours to complete

Faculty

Iain B. McInnes, PhD, FRCP, FRSE, FMedSci
Iain B. McInnes, PhD, FRCP, FRSE, FMedSci
Muirhead Chair of Medicine
Director of the Institute of Infection, Immunity, and Inflammation
University of Glasgow
Glasgow, Scotland


Marc D. Cohen, MD
Marc D. Cohen, MD
Emeritus Professor of Medicine, Mayo Clinic
Rochester, Minnesota
Adjunct Professor of Medicine
Division of Rheumatology, National Jewish Health
Denver, Colorado


Jeffrey R. Curtis, MD
Jeffrey R. Curtis, MD
Professor of Medicine
The William J. Koopman Endowed Professor
in Rheumatology and Immunology
Director, Arthritis Clinical Intervention Program
University of Alabama at Birmingham
Birmingham, Alabama


Jointly provided by

Commercial Support Statement

This activity is supported by an independent educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Method of Participation

Participants should read the activity information, review the activity in its entirety, and complete the online post-test and evaluation. Upon completing this activity as designed and achieving a passing score on the post-test, you will be directed to a Web page that will allow you to receive your certificate of credit via email or you may print it out at that time.

Inquiries may be directed to Global Academy for Medical Education at info@globalacademycme.com or (973) 290-8225 or the Postgraduate Institute for Medicine at (720) 895-5357.

Joint Accreditation Statement

Accreditation Council for Pharmacy Education In support of improving patient care, this activity has been planned and implemented by Postgraduate Institute for Medicine and Global Academy for Medical Education. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.

Physician Continuing Medical Education

Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Target Audience

This enduring activity is intended for rheumatologists, internal medicine physicians with a secondary specialty in rheumatology, physician assistants, and other clinicians who treat patients with rheumatic diseases.

Educational Needs

Clinical studies on patients with rheumatoid arthritis have consistently found that patients are more likely to respond and more likely to reach remission if they are treated with disease-modifying antirheumatic drugs (DMARDs) within 3 to 6 months of symptom onset. But studies of patients in clinical practice find that diagnosis is often delayed, and typically treatment begins a year or more after symptom onset. Clinicians need information on strategies to enable earlier treatment. Guidelines also recommend a treat-to-target approach with a goal of sustained remission. This approach requires ongoing monitoring and treatment changes to meet patient needs. New medications have been approved recently, adding to the rheumatologist’s armamentarium for treating rheumatoid arthritis.

Learning Objectives

At the conclusion of this program, participants should be better able to:

  • Design appropriate strategies to increase the timeliness of rheumatoid arthritis diagnosis and subsequent linkage to evidence-based care
  • Design appropriate strategies to relieve articular and systemic symptoms of rheumatoid arthritis
  • Design strategies for using the most appropriate therapies based on the safety and efficacy data of the emerging classes of therapies for rheumatoid arthritis, including anti-interleukin (IL)-6/IL-6R agents, tumor necrosis factor (TNF) inhibitors, and other biologic disease-modifying antirheumatic drugs (DMARDs)
  • Design treatment strategies for rheumatoid arthritis that take into consideration recommendations from current guidelines and emerging data from clinical trials
  • Describe the data presented at national and global scientific conferences that may help clinicians achieve the treatment goals for rheumatoid arthritis

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COIs are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity.

Marc D. Cohen, MD, has nothing to disclose.

Jeffrey R. Curtis, MD, Consultant: AbbVie, Amgen, Bristol-Myers Squibb, Corrona, Crescendo Bioscience, Ortho-McNeil-Janssen Pharmaceuticals, Pfizer, and UCB. Grant/Research Support: AbbVie, Amgen, Bristol-Myers Squibb, Corrona, Crescendo Bioscience, Ortho-McNeil-Janssen Pharmaceuticals, Roche/Genentech, Pfizer, and UCB.

Iain B. McInnes, PhD, FRCP, FRSE, FMedSci, Consultant: AbbVie, Galapagos, Lilly, and Pfizer. Grant/Research Support: Bristol-Myers Squibb, Janssen, Pfizer, and UCB.

The planning staff and content managers hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Global Academy for Medical Education Staff: Mike LoPresti; Shirley V. Jones, MBA; and Margaret McLauglin, PhD, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Postgraduate Institute for Medicine: planners and managers have nothing to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

1.00 CME / CNE
Postgraduate Institute for Medicine
Clinical Conversations™: Achieving Success in RA Assessment and Management

Clinical Conversations™: Achieving Success in RA Assessment and Management

Start

Jointly Provided By

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and RMEI Medical Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Activity Details

Free CME/CNE
1.0 AMA PRA Category 1 Credit
1.0 ANCC contact hour
0.5 APRN contact hour
Released: February 27, 2018
Expires: February 27, 2019
1 hour to complete

Media

Internet

Target Audience

This activity has been designed to meet the educational needs of clinicians who manage patients with rheumatoid arthritis (RA).

Learning Objectives

After completing this activity, the participant will demonstrate the ability to:

  1. Discriminate between the effects of the tumor necrosis factor alpha (TNFα) and interleukin 6 (IL-6) signaling pathways in the pathophysiology of RA and provide a rationale for anti-cytokine therapy as a treatment approach
  2. Incorporate validated and guideline-recommended disease activity monitoring to guide appropriate management for patients with RA
  3. Develop individualized treatment plans for patients with rheumatoid arthritis that integrate new and emerging targeted and non-TNF disease modifying antirheumatic drugs (dMARDs) based on safety and efficacy data
  4. Distinguish between TNF cycling and switching and prepare treatment plans that improve patient outcomes based on an understanding of the differences between the 2 options
  5. Integrate shared decision making and other patient education strategies for patients with RA

Activity Description

This exciting interactive activity in RA features 2 patient cases, challenging questions related to the cases, and video vignettes of the real patients presented during the activity. You will have an opportunity to hear from our expert faculty and learn from the patients' perspectives. Effective management of RA requires appropriate treatment selection up front, regular disease activity monitoring, and patient engagement. New and novel treatment approaches will also be discussed.

Faculty

Martin Jan Bergman, MD, FACR, FACP, FCPP
Clinical Associate Professor of Medicine
Drexel University School of Medicine
Philadelphia, PA
Chief, Division of Rheumatology
Taylor Hospital
Ridley Park, PA


Sergio Schwartzman, MD
Franchellie M. Cadwell Associate Professor of Clinical Medicine
Weill Cornell Medical College
Associate Attending Physician
New York Presbyterian Hospital
Hospital for Special Surgery
New York, NY


Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

  • Martin Jan Bergman, MD, FACR, FACP, FCPP, has affiliations with AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Genentech, GlaxoSmithKline, Janssen, Novartis, Pfizer, and Sanofi (Advisory Boards); AbbVie, Celgene, Novartis, Pfizer, and Sanofi (Fees for Non-CME/CE Services Received Directly from a Commercial Interest or Their Agents); and Johnson & Johnson, Merck, and Pfizer (Ownership Interest).

  • Sergio Schwartzman, MD, has affiliations with AbbVie, Crescendo, Genentech, Hospira, Janssen, Novartis, Pfizer, Regeneron, Sanofi, and UCB (Speaker’s Bureau); Amgen, Gilead, Medtronic, and Pfizer (Ownership Interest); AbbVie, Crescendo, Epirus, Genentech, Hospira, Janssen, Lilly, Novartis, Pfizer, Regeneron, and Sanofi (Consulting Fees); and Crescendo (Advisory Board).

RMEI Medical Education, LLC

  • Jacqui Brooks, MBBCh, MRCPsych, has no affiliations with commercial interests to disclose.
  • Lobna M. Eldasher, PharmD, has no affiliations with commercial interests to disclose.
  • Tania Dickson, PhD, has no affiliations with commercial interests to disclose.
  • Sharon Powell, has no affiliations with commercial interests to disclose.

Postgraduate Institute for Medicine
The following PIM planners and managers, Judi Smelker-Mitchek, RN, BSN; Trace Hutchison, PharmD; Samantha Mattiucci, PharmD, CHCP; and Jan Schultz, MSN, RN, CHCP, have nothing to disclose.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hours.
Designated for 0.5 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.

How to Receive Credit

By reviewing the course content and successfully completing the post-test and evaluation, physicians, nurse practitioners, and PAs are entitled to receive up to 1 AMA PRA Category 1 Credit(s)™, 1.0 ANCC contact hour, and 0.5 APRN contact hour. A statement of credit will be available to print from your user history page. Users must:

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the activity evaluation.

Physicians, nurse practitioners, and PAs who successfully complete the post-test and evaluation will receive CME credit. You must score 75% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.

Statement of Commercial Support

This activity is jointly provided by Postgraduate Institute for Medicine and RMEI Medical Education, LLC. This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 9.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

0.50 CME
Postgraduate Institute for Medicine
The Impact of Earlier Diagnosis and Timelier Treatment of Rheumatoid Arthritis on Patient Outcomes and Healthcare Systems

The Impact of Earlier Diagnosis and Timelier Treatment of Rheumatoid Arthritis on Patient Outcomes and Healthcare Systems

Start

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit
Released: December 28, 2017
Expires: December 27, 2018

Jointly provided by


Learning Objectives

After completing this activity, the participant will demonstrate the ability to:

  • Apply the research that defined the benefits associated with early diagnosis and treatment of RA

Faculty

Marc D. Cohen, MD
Emeritus Professor of Medicine
Mayo Clinic
Rochester, Minnesota
Adjunct Professor of Medicine
Division of Rheumatology
National Jewish Health
Denver, Colorado

Iain B. McInnes, FRCP, PhD, FRSE, FMedSci
Muirhead Chair of Medicine
Director of the Institute of Infection, Immunity, and Inflammation
University of Glasgow
Glasgow, Scotland

Program Overview

Delays in diagnoses and early intervention of rheumatic and musculoskeletal diseases, including rheumatoid arthritis (RA), can cause unnecessary disease progression, reduce chances of remission, decrease patients' quality of life, increase co-morbidities, reduce life expectancy, and increase the added cost burden on global healthcare systems. A growing body of evidence supports the concept of a window of opportunity (3 to 6 months after onset of symptoms) during which initiating treatment for RA can relieve symptoms, minimize comorbidities, and reduce the risk for progression and long-term disability. Global medical society guidelines have been revised recently to underscore the importance of earlier diagnosis of RA and to encourage the earlier use of disease modifying antirheumatic drugs (DMARDs) involving a treat-to-target strategy. Clinicians need education about these developments, about the use of established and emerging therapeutic agents for RA, and about strategies for preparing their practices to better manage patients earlier in the course of rheumatic disease.

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Global Academy of Medical Education. Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Term of Offering

This activity was released on December 28, 2017 and is valid for one year. Requests for credit must be made no later than December 27, 2018.

Instructions for Obtaining Credit

In order to receive credit, participants must complete the online evaluation and post-test at the end of this program. Participants must also score at least a 70% on the post-test. Statements of credit will be issued upon completion of the evaluation and post-test.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Disclosure Declarations

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Marc Cohen, MD
Has nothing to disclose.

Iain B. McInnes, FRCP, PhD, FRSE, FMedSci
Consultant: AbbVie; Galapagos Pharma; Lilly; Pfizer.
Grant/Research Support: Bristol- Myers Squibb; Janssen; Pfizer; UCB.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Mike LoPresti
Nothing to disclose

Margaret McLaughlin, PhD
Nothing to disclose

Ron Schaumburg
Nothing to disclose

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Commercial Support Statement

This activity is supported by an educational grant from Sanofi-Regeneron.

Course Viewing Requirements

Supported Browsers:

Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:

Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.

Copyright © 2018 by Global Academy for Medical Education, LLC, Frontline Medical Communications Inc., and its Licensors. All rights reserved. No part of this publication may be reproduced or transmitted in any form, by any means, without prior written permission of the Publisher. Global Academy for Medical Education, LLC, and Postgraduate Institute for Medicine will not assume responsibility for damages, loss, or claims of any kind arising from or related to the information contained in this publication, including any claims related to the products, drugs, or services mentioned herein.

0.50 CME
Postgraduate Institute for Medicine
Effective Practice Strategies to Achieve Earlier RA Diagnosis and Faster Initiation of Care

Effective Practice Strategies to Achieve Earlier RA Diagnosis and Faster Initiation of Care

Start

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit
Released: December 28, 2017
Expires: December 27, 2018

Jointly provided by

Learning Objectives

After completing this activity, the participant will demonstrate the ability to:

  • Design appropriate evidence-based strategies for increasing the timeliness both of the diagnosis of rheumatoid arthritis and the initiation of treatment

Faculty

Iain B. McInnes, FRCP, PhD, FRSE, FMedSci
Muirhead Chair of Medicine
Director of the Institute of Infection, Immunity, and Inflammation
University of Glasgow
Glasgow, Scotland

Marc D. Cohen, MD
Emeritus Professor of Medicine
Mayo Clinic
Rochester, Minnesota
Adjunct Professor of Medicine
Division of Rheumatology
National Jewish Health
Denver, Colorado

Jeffrey R. Curtis, MD
Professor of Medicine
The William J. Koopman Endowed Professor in Rheumatology and Immunology
Director, Arthritis Clinical Intervention Program
University of Alabama, Birmingham

Program Overview

Delays in diagnoses and early intervention of rheumatic and musculoskeletal diseases, including rheumatoid arthritis (RA), can cause unnecessary disease progression, reduce chances of remission, decrease patients' quality of life, increase co-morbidities, reduce life expectancy, and increase the added cost burden on global healthcare systems. A growing body of evidence supports the concept of a window of opportunity (3 to 6 months after onset of symptoms) during which initiating treatment for RA can relieve symptoms, minimize comorbidities, and reduce the risk for progression and long-term disability. Global medical society guidelines have been revised recently to underscore the importance of earlier diagnosis of RA and to encourage the earlier use of disease modifying antirheumatic drugs (DMARDs) involving a treat-to-target strategy. Clinicians need education about these developments, about the use of established and emerging therapeutic agents for RA, and about strategies for preparing their practices to better manage patients earlier in the course of rheumatic disease.

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Global Academy of Medical Education. Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Term of Offering

This activity was released on December 28, 2017 and is valid for one year. Requests for credit must be made no later than December 27, 2018.

Instructions for Obtaining Credit

In order to receive credit, participants must complete the online evaluation and post-test at the end of this program. Participants must also score at least a 70% on the post-test. Statements of credit will be issued upon completion of the evaluation and post-test.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Disclosure Declarations

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Marc Cohen, MD
Has nothing to disclose.

Iain B. McInnes, FRCP, PhD, FRSE, FMedSci
Consultant: AbbVie; Galapagos Pharma; Lilly; Pfizer.
Grant/Research Support: Bristol- Myers Squibb; Janssen; Pfizer; UCB.

Jeffrey Curtis, MD
Consultant: AbbVie, Amgen, Bristol- Myers Squibb, Crescendo Bioscience, Inc, CORRONA, Ortho-McNeil- Janssen Pharmaceutical Company, Pfizer Inc., and UCB.
Grant/Research Support: AbbVie Inc, Amgen, Inc, Bristol-Myers Squibb, Crescendo Bioscience, Inc, CORRONA, Ortho-McNeil- Janssen Pharmaceutical Company, Roche/Genentech, Pfizer Inc., and UCB.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Mike LoPresti
Nothing to disclose

Margaret McLaughlin, PhD
Nothing to disclose

Ron Schaumburg
Nothing to disclose

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Commercial Support Statement

This activity is supported by an educational grant from Sanofi-Regeneron.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.

Copyright © 2018 by Global Academy for Medical Education, LLC, Frontline Medical Communications Inc., and its Licensors. All rights reserved. No part of this publication may be reproduced or transmitted in any form, by any means, without prior written permission of the Publisher. Global Academy for Medical Education, LLC, and Postgraduate Institute for Medicine will not assume responsibility for damages, loss, or claims of any kind arising from or related to the information contained in this publication, including any claims related to the products, drugs, or services mentioned herein.

1.00 CME / CNE
Postgraduate Institute for Medicine
Clinical Convergence®: Achieving Success in RA Assessment and Management

Clinical Convergence®: Achieving Success in RA Assessment and Management

Start

Jointly Provided By

Activity Details

Free CME/CNE
1.0 AMA PRA Category 1 Credit
1.0 ANCC contact hour
0.5 APRN contact hour
Released: December 26, 2017
Expires: December 26, 2018
1 hour to complete

Media

Internet

Target Audience

This activity has been designed to meet the educational needs of clinicians who manage patients with rheumatoid arthritis (RA).

Learning Objectives

After completing this activity, the participant will demonstrate the ability to:

  1. Discriminate between the effects of the tumor necrosis factor alpha (TNFα) and interleukin 6 (IL-6) signaling pathways in the pathophysiology of rheumatoid arthritis (RA) and provide a rationale for anti-cytokine therapy as a treatment approach
  2. Incorporate validated and guideline-recommended disease activity monitoring to guide appropriate management for patients with RA
  3. Develop individualized treatment plans for patients with RA that integrate new and emerging targeted and non-TNF disease modifying antirheumatic drugs (dMARDs) based on safety and efficacy data
  4. Distinguish between TNF cycling and switching and prepare treatment plans that improve patient outcomes based on an understanding of the differences between the 2 options
  5. Integrate shared decision making and other patient education strategies for patients with RA

Activity Description

This exciting interactive activity in rheumatoid arthritis (RA) features 2 patient cases, challenging questions related to the cases, and video vignettes of the real patients presented during the activity. You will have an opportunity to hear from our expert faculty and learn from the patients' perspectives. Effective management of RA requires appropriate treatment selection up front, regular disease activity monitoring, and patient engagement. New and novel treatment approaches will also be discussed.

Faculty

Martin Jan Bergman, MD, FACR, FACP, FCPP
Clinical Associate Professor of Medicine
Drexel University School of Medicine
Philadelphia, PA
Chief, Division of Rheumatology
Taylor Hospital
Ridley Park, PA


Sergio Schwartzman, MD
Franchellie M. Cadwell Associate Professor of Clinical Medicine
Weill Cornell Medical College
Associate Attending Physician
New York Presbyterian Hospital
Hospital for Special Surgery
New York, NY


Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COIs are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

  • Martin Jan Bergman, MD, FACR, FACP, FCPP, has affiliations with AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Genentech, GlaxoSmithKline, Janssen, Novartis, Pfizer, and Sanofi (Advisory Boards); AbbVie, Celgene, Novartis, and Sanofi (Fees for Non-CME/CE Services Received Directly from a Commercial Interest or Their Agents); and Johnson & Johnson, Merck, and Pfizer (Ownership Interest).
  • Sergio Schwartzman, MD, has affiliations with AbbVie, Crescendo, Genentech, Hospira, Janssen, Novartis, Pfizer, Regeneron, Sanofi, and UCB (Speaker’s Bureau); Amgen, Gilead, Medtronic, and Pfizer (Ownership Interest); AbbVie, Crescendo, Epirus, Genentech, Hospira, Janssen, Lilly, Novartis, Pfizer, Regeneron, and Sanofi (Consulting Fees); and Crescendo (Advisory Board).

RMEI Medical Education, LLC

  • Jacqui Brooks, MBBCh, MRCPsych, has no affiliations with commercial interests to disclose.
  • Tania Dickson, PhD, has no affiliations with commercial interests to disclose.
  • Sharon Powell has no affiliations with commercial interests to disclose.

Postgraduate Institute for Medicine
The following PIM planners and managers, Judi Smelker-Mitchek, RN, BSN, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, and Jan Schultz, MSN, RN, CHCP, have nothing to disclose.

Physician Continuing Medical Education

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and RMEI Medical Education, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education

The Postgraduate Institute for Medicine is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. This educational activity for 1.0 contact hour is provided by the Postgraduate Institute for Medicine. Designated for 0.5 contact hour of pharmacotherapy credit for Advance Practice Registered Nurses.

How to Receive Credit

By reviewing the course content and successfully completing the post-test and evaluation, physicians, nurse practitioners, and PAs are entitled to receive up to 1.0 AMA PRA Category 1 Credit(s)™, 1.0 ANCC contact hour, and 0.5 APRN contact hour. A statement of credit will be available to print from your user history page. Users must:

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the activity evaluation.

Physicians, nurse practitioners, and PAs who successfully complete the post-test and evaluation will receive CME credit. You must score 75% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.

Statement of Commercial Support

This activity is jointly provided by Postgraduate Institute for Medicine and RMEI Medical Education, LLC. This activity is supported by an educational grant from Sanofi, Genzyme, and Regeneron Pharmaceuticals.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 9.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

1.00 CME / CNE
Postgraduate Institute for Medicine
Clinical Reflections®: Achieving Success in RA Assessment and Management: A Learner Pathway to Improve Patient Outcomes

Clinical Reflections®: Achieving Success in RA Assessment and Management: A Learner Pathway to Improve Patient Outcomes

Start

Jointly Provided By

Activity Details

Free CME/CNE
1 AMA PRA Category 1 Credit
1 ANCC contact hour
0.5 APRN contact hour
Released: October 12, 2017
Expires: October 12, 2018
1 hour to complete
No registration required

Media

Internet

Target Audience

This activity has been designed to meet the educational needs of clinicians and registered nurses who manage patients with rheumatoid arthritis (RA).

Learning Objectives

After completing this activity, the participant will demonstrate the ability to:

  1. Discriminate between the effects of the tumor necrosis factor alpha (TNFα) and interleukin 6 (IL-6) signaling pathways in the pathophysiology of rheumatoid arthritis (RA) and provide a rationale for anti-cytokine therapy as a treatment approach
  2. Incorporate validated and guideline-recommended disease activity monitoring to guide appropriate management for patients with rheumatoid arthritis
  3. Develop individualized treatment plans for patients with rheumatoid arthritis that integrate new and emerging targeted and non-TNF disease modifying antirheumatic drugs (bMARDs) based on safety and efficacy data
  4. Distinguish between TNF cycling and switching and prepare treatment plans that improve patient outcomes based on an understanding of the differences between the 2 options
  5. Integrate shared decision making and other patient education strategies for patients with rheumatoid arthritis

Activity Description

Rheumatoid arthritis (RA) is a chronic disease with devastating consequences if not optimally managed early in the disease process. To effectively treat RA, appropriate treatments need to be selected, disease and treatment outcomes must be measured regularly, and patients need to be engaged in their own care. These concepts underpin the treat-to-target (T2T) approach endorsed by the European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR). The availability of several new treatments beyond conventional disease modifying antirheumatic drugs (DMARDs) and anti-tumor necrosis factor (anti-TNF) inhibitors also increases the complexity of effective disease management.

This unique educational initiative harnesses the power of reflection and recognition of suboptimal approaches to patient management to allow you to rethink clinical decisions based on the scenarios presented and to modify management plans accordingly. You can compare your responses to interactive questions with those of your peers and learn from our expert faculty.

Faculty

Jeffrey R. Curtis, MD, MS, MPH (Chair)
William J. Koopman Endowed Professor in Rheumatology and Immunology
Professor of Medicine, Division of Clinical Immunology and Rheumatology
Director, University of Alabama at Birmingham (UAB) Arthritis Clinical Intervention     Program
Co-Director, UAB Center for Education and Research on Therapeutics (CERTS) of Musculoskeletal Disorders
Co-Director, UAB Pharmacoepidemiology and Pharmacoeconomics (PEER) Unit
University of Alabama at Birmingham
Birmingham, AL


Martin Jan Bergman, MD, FACR, FACP, FCPP
Clinical Associate Professor of Medicine
Drexel University School of Medicine
Philadelphia, PA
Chief, Division of Rheumatology
Taylor Hospital
Ridley Park, PA


Peter C. Taylor, MA, BM, BCh, PhD, FRCP, FRCPE
Norman Collison Professor of Musculoskeletal Sciences
Fellow, St. Peter’s College
Head of Clinical Sciences, Biomedical Research Unit Inflammation Theme
Botnar Research Centre
University of Oxford
Oxford, England (UK)


Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

  • Jeffrey R. Curtis, MD, MS, MPH, has affiliations with AbbVie, Amgen, Bristol-Myers Squibb, Corrona, Genentech, Janssen, Lilly, Myriad, and Pfizer (Consulting Fees); and AbbVie, Amgen, Bristol-Myers Squibb, Corrona, Genentech, Janssen, Lilly, Myriad, and Pfizer (Contracted Research).
  • Martin Jan Bergman, MD, FACR, FACP, FCPP, has affiliations with AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Genentech, GlaxoSmithKline, Janssen, Novartis, Pfizer, and Sanofi (Consulting Fees); AbbVie, Celgene, Novartis, and Sanofi (Fees for Non-CME/CE Services Received Directly from a Commercial Interest or Their Agents); Johnson & Johnson, Merck, and Pfizer (Ownership Interest).
  • Peter C. Taylor, MA, BM, BCh, PhD, FRCP, FRCPE, has affiliations with AbbVie, Biogen, Galapagos, GlaxoSmithKline, Janssen, Lilly, Pfizer, Sanofi, and UCB (Consulting Fees); and Abide Therapeutics, Celgene, Lilly, and UCB (Contracted Research).

RMEI Medical Education, LLC

  • Jacqui Brooks, MBBCh, MRCPsych, has no affiliations with commercial interests relative to the content to disclose.
  • Tania Dickson, PhD, has no affiliations with commercial interests relative to the content to disclose.
  • Jessica Hatch has no affiliations with commercial interests to disclose.

Postgraduate Institute for Medicine
The following PIM planners and managers, Judi Smelker-Mitchek, RN, BSN, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, and Jan Schultz, MSN, RN, CHCP, have nothing to disclose.

Physician Continuing Medical Education

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and RMEI Medical Education, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Postgraduate Institute for Medicine is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.  This educational activity for 1 contact hour is provided by the Postgraduate Institute for Medicine. Designated for 0.5 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.

How to Receive Credit

By reviewing the course content and successfully completing the post test and evaluation, physicians, nurse practitioners, and PAs are entitled to receive up to 1 AMA PRA Category 1 Credit(s)™, 1 ANCC contact hour, and 0.5 APRN contact hours. A statement of credit will be available to print from your user history page. Users must:

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the activity evaluation.

Physicians, nurse practitioners, and PAs who successfully complete the post test and evaluation will receive CME credit. You must score 75% or higher on the post test to receive credit for this activity. All other participants who successfully complete the post test and evaluation will receive a certificate of participation.

Statement of Commercial Support

This activity is supported by an independent educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 9.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

0.75 CME
Penn State College of Medicine
Examining the Crucial Coalition Between Dermatology and Rheumatology in Psoriatic Arthritis Treatment: Early Collaboration in the Treatment of PsA

Examining the Crucial Coalition Between Dermatology and Rheumatology in Psoriatic Arthritis Treatment: Early Collaboration in the Treatment of PsA

Start

Provided By

Activity Details

Free CME
0.75 AMA PRA Category 1 Credits
Released: October 6, 2017
Expires: October 6, 2018
45 minutes to complete

Target Audience

Rheumatologists, dermatologists, and allied health care professionals involved in the treatment of patients with psoriasis and PsA.

Learning Objectives

Upon completion of this educational activity, the participant should be able to:

  • Screen patients with psoriasis for inflammatory arthritides such as PsA.
  • Describe the consequences of delaying rheumatology referral of patients with psoriasis who have PsA.
  • Discuss the complementary skills and experience that a dermatologist and rheumatologist can each bring to the care of a patient with PsA.
  • Describe effective methods of inter-specialty communication that facilitate co-management of psoriasis patients with PsA.

Activity Description

Psoriatic arthritis (PsA) is a serious, inflammatory arthritis associated with psoriasis and multiple comorbidities that often goes undiagnosed and untreated. This activity will examine strategies for early recognition and referral, as well as specialty collaboration in the treatment of PsA.

Faculty

Eric M. Ruderman, MD
Professor of Medicine
Associate Chief, Clinical Affairs
Division of Rheumatology
Northwestern University
Feinberg School of Medicine
Chicago, IL

Dr. Ruderman has disclosed the following:
Consultant/Advisor: AbbVie, Amgen, BMS, Celltrion, Janssen, Lilly, Novartis, Pfizer
Research Grant: Pfizer


Joseph F. Merola, MD, MMSc
Assistant Professor of Medicine
Harvard Medical School
Director, Clinical Unit for Research Innovation and Trials (CUReIT)
Co-Director, Center for Skin and Related Musculoskeletal Diseases
Departments of Dermatology and Medicine
Division of Rheumatology
Brigham and Women's Hospital
Boston, MA

Dr. Merola has disclosed the following:
Speakers Bureau: AbbVie
Consultant/Advisor: AbbVie, Amgen, Biogen, GSK, Janssen, Kiniksa, Lilly, Mallinckrodt, Momenta, Novartis, Pfizer, Samumed, Sanofi, Science 37, UCB


Conflict of Interest Policy/Disclosure Statement

It is our policy to ensure balance, independence, objectivity, and scientific rigor in all of our educational programs. Faculty and course directors have disclosed relevant financial relationships with commercial companies, and Penn State has a process in place to resolve any conflict of interest.

Penn State staff involved in the development and review of this activity have nothing to disclose.

MCM Education staff involved in the development and review of this activity have nothing to disclose.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine and MCM Education. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

Penn State College of Medicine designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

  • Click "Start Program"
  • Take the pre-test
  • Review the activity
  • Take the post-test and score 80%
  • You are allowed a total of 3 attempts
  • Complete the evaluation
  • View, print, or save a CME certificate verifying your credit/participation in this activity

Statement of Commercial Support

This activity is supported by independent educational grants from Novartis and AbbVie.

Disclaimer Statement/Disclosure of Unlabeled Use

The opinions expressed in this educational activity are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions; the publisher; Penn State College of Medicine; Novartis; or AbbVie. Any medications, diagnostic procedures, or treatments discussed by the program presenters should not be used by clinicians or other health care professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.

Faculty members are required to inform the audience when they are discussing off-label or unapproved uses of devices or drugs. Devices or drugs that are still undergoing clinical trials are identified as such and should not be portrayed as standard, accepted therapy. Please consult full prescribing information before using any product mentioned in this activity. If using products in an investigational, off-label manner, it is the responsibility of the prescribing physician to monitor the medical literature to determine recommended dosages and uses of the drugs. Neither the publisher nor the providers promote the use of any agent outside of approved labeling.

Contact Information for Questions About the Activity

MCM Education
17 Blacksmith Road
Suite 100
Newtown, PA 18940
info@cmecorner.com

Hardware/Software Requirements

Computer Requirements: Minimum System Requirements: • Pentium III, 600 MHz or Equivalent Processor • 512 MB of RAM • Windows XP, Vista, or 7 • Mac OS X • 800x600 Monitor Resolution • 16-bit Color • 16 bit Sound Card with Speakers

0.75 CME
Penn State College of Medicine
Examining the Crucial Coalition Between Dermatology and Rheumatology in Psoriatic Arthritis Treatment: The Importance of Continued Co-management in the Treatment of PsA

Examining the Crucial Coalition Between Dermatology and Rheumatology in Psoriatic Arthritis Treatment: The Importance of Continued Co-management in the Treatment of PsA

Start

Provided By

Activity Details

Free CME
0.75 AMA PRA Category 1 Credits
Released: October 6, 2017
Expires: October 6, 2018
45 minutes to complete

Target Audience

Rheumatologists, dermatologists, and allied health care professionals involved in the treatment of patients with psoriasis and PsA.

Learning Objectives

Upon completion of this educational activity, the participant should be able to:

  • Discuss the complementary skills and experience that a dermatologist and rheumatologist can each bring to the care of a patient with PsA.
  • Describe effective methods of inter-specialty communication that facilitate co-management of psoriasis patients with PsA.
  • Discuss the efficacy and safety of currently approved medications for the treatment of PsA.
  • Describe guideline-recommended use of available agents for the treatment of patients with psoriasis and PsA.

Activity Description

Psoriatic arthritis (PsA) is a serious, inflammatory arthritis associated with psoriasis and multiple comorbidities that often requires collaborative care between dermatologists, rheumatologists, and primary care clinicians. This activity will examine specialty collaboration and guideline-recommended treatment.

Faculty

Eric M. Ruderman, MD
Professor of Medicine
Associate Chief, Clinical Affairs
Division of Rheumatology
Northwestern University
Feinberg School of Medicine
Chicago, IL

Dr. Ruderman has disclosed the following:
Consultant/Advisor: AbbVie, Amgen, BMS, Celltrion, Janssen, Lilly, Novartis, Pfizer
Research Grant: Pfizer


Joseph F. Merola, MD, MMSc
Assistant Professor of Medicine
Harvard Medical School
Director, Clinical Unit for Research Innovation and Trials (CUReIT)
Co-Director, Center for Skin and Related Musculoskeletal Diseases
Departments of Dermatology and Medicine
Division of Rheumatology
Brigham and Women's Hospital
Boston, MA

Dr. Merola has disclosed the following:
Speakers Bureau: AbbVie
Consultant/Advisor: AbbVie, Amgen, Biogen, GSK, Janssen, Kiniksa, Lilly, Mallinckrodt, Momenta, Novartis, Pfizer, Samumed, Sanofi, Science 37, UCB


Conflict of Interest Policy/Disclosure Statement

It is our policy to ensure balance, independence, objectivity, and scientific rigor in all of our educational programs. Faculty and course directors have disclosed relevant financial relationships with commercial companies, and Penn State has a process in place to resolve any conflict of interest.

Penn State staff involved in the development and review of this activity have nothing to disclose.

MCM Education staff involved in the development and review of this activity have nothing to disclose.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine and MCM Education. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

Penn State College of Medicine designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

  • Click "Start Program"
  • Take the pre-test
  • Review the activity
  • Take the post-test and score 80%
  • You are allowed a total of 3 attempts
  • Complete the evaluation
  • View, print, or save a CME certificate verifying your credit/participation in this activity

Statement of Commercial Support

This activity is supported by independent educational grants from Novartis and AbbVie.

Disclaimer Statement/Disclosure of Unlabeled Use

The opinions expressed in this educational activity are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions; the publisher; Penn State College of Medicine; Novartis; or AbbVie. Any medications, diagnostic procedures, or treatments discussed by the program presenters should not be used by clinicians or other health care professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.

Faculty members are required to inform the audience when they are discussing off-label or unapproved uses of devices or drugs. Devices or drugs that are still undergoing clinical trials are identified as such and should not be portrayed as standard, accepted therapy. Please consult full prescribing information before using any product mentioned in this activity. If using products in an investigational, off-label manner, it is the responsibility of the prescribing physician to monitor the medical literature to determine recommended dosages and uses of the drugs. Neither the publisher nor the providers promote the use of any agent outside of approved labeling.

Contact Information for Questions About the Activity

MCM Education
17 Blacksmith Road
Suite 100
Newtown, PA 18940
info@cmecorner.com

Hardware/Software Requirements

Computer Requirements: Minimum System Requirements: • Pentium III, 600 MHz or Equivalent Processor • 512 MB of RAM • Windows XP, Vista, or 7 • Mac OS X • 800x600 Monitor Resolution • 16-bit Color • 16 bit Sound Card with Speakers